Skip to main content
. 2021 Nov 29;12(6):358–362. doi: 10.14740/cr1333

Table 2. Changes in Metabolic Parameters After Switching From Fenofibrate to Pemabibrate.

Baseline After 3 months After 6 months After 12 months
Aspartate aminotransferase (IU/L) 79.1 ± 194.1 63.6 ± 148.4 34.4 ± 35.7 26.7 ± 8.5
Alanine aminotransferase (IU/L) 37.4 ± 31.1 31.1 ± 20.9 27.8 ± 18.6* 34.7 ± 27.1
γ-glutamyl transpeptidase (IU/L) 144.8 ± 319.8 83.4 ± 140.7 94.2 ± 160.9 92.0 ± 154.8
Creatine phosphokinase (IU/L) 100.1 ± 72.4 110.2 ± 64.2 100.6 ± 37.5 136.3 ± 139.5
Plasma glucose (mg/dL) 148.9 ± 42.9 164.6 ± 53.1 150.1 ± 34.4 162.5 ± 41.6
HbA1c (%) 7.0 ± 1.2 6.9 ± 0.9 6.8 ± 0.8 6.9 ± 0.8
Total cholesterol (mg/dL) 216.7 ± 70.3 201.4 ± 34.2 191.4 ± 15.4 186.1 ± 30.8
Triglyceride (mg/dL) 346.3 ± 468.5 314.3 ± 335.8 203.9 ± 105.4 217.5 ± 123.0
HDL-cholesterol (mg/dL) 55.5 ± 27.5 47.4 ± 10.1 47.8 ± 10.8 51.7 ± 11.9
LDL-cholesterol (mg/dL) 108.7 ± 18.5 112.0 ± 16.9 116.8 ± 15.4 108.4 ± 26.5
Non-HDL-cholesterol (mg/dL) 161.2 ± 72.9 154.0 ± 34.3 143.6 ± 10.7 134.4 ± 30.9

*P < 0.05 vs. baseline.